Nitrase Therapeutics
Prasanna Kandel is a Senior Scientist and Assay Development Leader at Nitrase Therapeutics since January 2023, having previously held positions as Staff Scientist and Scientist in the same area. Prior to this, Kandel was a Specialist/Staff Scientist focused on drug discovery at the Small Molecule Discovery Center at UCSF from June 2021 to January 2023. Kandel's academic background includes a PhD in Integrative Molecular and Biomedical Sciences from Baylor College of Medicine, where Kandel also completed a postdoctoral associate role in Pharmacology and Chemical Biology as well as served as a graduate student from August 2014 to May 2021. Kandel earned a Bachelor of Science in Chemistry from Boise State University between 2009 and 2014.
This person is not in any teams
This person is not in any offices
Nitrase Therapeutics
1 followers
Nitrase Therapeutics is a pioneering biopharmaceutical company deploying its unique NITROME platform to unlock the therapeutic potential of nitrases, a new class of enzymes that it discovered, to develop a pipeline of therapies against a broad variety of diseases. The medicines that Nitrase Therapeutics is developing will target these enzymes and potentially help slow or halt the progression of a wide variety of diseases in which nitrases and nitro-substrates play a role, including Parkinson’s and cancer. Nitrase Therapeutics (under the former name Nitrome Biosciences) has been widely recognized and has won multiple awards including the prestigious Target Advancement grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF).